WO2003105772A3 - PARATHYROID HORMONE ANALOGS AND PARATHYROID HORMONE-RELATED PROTEIN AS BONE ANABOLIZING AGENTS - Google Patents

PARATHYROID HORMONE ANALOGS AND PARATHYROID HORMONE-RELATED PROTEIN AS BONE ANABOLIZING AGENTS Download PDF

Info

Publication number
WO2003105772A3
WO2003105772A3 PCT/US2003/018890 US0318890W WO03105772A3 WO 2003105772 A3 WO2003105772 A3 WO 2003105772A3 US 0318890 W US0318890 W US 0318890W WO 03105772 A3 WO03105772 A3 WO 03105772A3
Authority
WO
WIPO (PCT)
Prior art keywords
parathyroid hormone
anabolizing
bone
agents
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/018890
Other languages
French (fr)
Other versions
WO2003105772A2 (en
Inventor
Michael Chorev
Michael Rosenblatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc
Priority to AU2003251527A priority Critical patent/AU2003251527A1/en
Priority to US10/516,224 priority patent/US7799757B2/en
Priority to EP03760386A priority patent/EP1551438A2/en
Publication of WO2003105772A2 publication Critical patent/WO2003105772A2/en
Publication of WO2003105772A3 publication Critical patent/WO2003105772A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de nouveaux analogues d'hormone parathyroïde et de nouveaux analogues de protéine liée à l'hormone parathyroïde. L'invention concerne également des procédés d'utilisation de ces analogues pour traiter l'ostéoporose, promouvoir la formation osseuse et inhiber la perte osseuse.The present invention relates to novel analogs of parathyroid hormone and novel analogs of protein linked to parathyroid hormone. The invention also relates to methods of using these analogs to treat osteoporosis, promote bone formation and inhibit bone loss.

PCT/US2003/018890 2002-06-13 2003-06-13 Analogs of parathyroid hormone and pth-related protein as bone anabolic agents Ceased WO2003105772A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003251527A AU2003251527A1 (en) 2002-06-13 2003-06-13 Analogs of parathyroid hormone and pth-related protein as bone anabolic agents
US10/516,224 US7799757B2 (en) 2002-06-13 2003-06-13 Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents
EP03760386A EP1551438A2 (en) 2002-06-13 2003-06-13 Analogs of parathyroid hormone and pth-related protein as bone anabolic agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38891802P 2002-06-13 2002-06-13
US60/388,918 2002-06-13
US39800502P 2002-07-23 2002-07-23
US60/398,005 2002-07-23

Publications (2)

Publication Number Publication Date
WO2003105772A2 WO2003105772A2 (en) 2003-12-24
WO2003105772A3 true WO2003105772A3 (en) 2004-04-08

Family

ID=29740073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/018890 Ceased WO2003105772A2 (en) 2002-06-13 2003-06-13 Analogs of parathyroid hormone and pth-related protein as bone anabolic agents

Country Status (4)

Country Link
US (1) US7799757B2 (en)
EP (1) EP1551438A2 (en)
AU (1) AU2003251527A1 (en)
WO (1) WO2003105772A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288253B2 (en) 2003-08-08 2007-10-30 Amgen Fremont, Inc. Antibodies directed to parathyroid hormone (PTH) and uses thereof

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
BRPI0618469A2 (en) * 2005-11-10 2011-08-30 Univ Michigan Tech black bear parathyroid hormone and methods of using black bear parathyroid hormone
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
CA2664734C (en) * 2006-10-03 2023-08-01 Radius Health, Inc. Method of drug delivery for bone anabolic protein
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
BRPI0719885B8 (en) * 2006-10-13 2021-05-25 Lilly Co Eli pegylated peptides as pth receptor modulators, their uses, and composition.
EP2411038B1 (en) 2009-03-27 2016-12-28 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
CA2782640A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
PT2568806T (en) 2010-05-12 2016-08-05 Radius Health Inc Therapeutic regimens
CN102399285B (en) * 2011-05-31 2014-06-04 成都金凯生物技术有限公司 Parathyroid hormone (PTH) derivative
CN102993293B (en) * 2012-12-05 2014-05-07 深圳翰宇药业股份有限公司 Method for purifying teriparatide acetate
EP3016674A4 (en) * 2013-06-23 2017-03-15 Wisconsin Alumni Research Foundation Alpha-/beta-polypeptide analogs of parathyroid hormone (pth) and method of using same
RS67458B1 (en) 2014-03-28 2025-12-31 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
KR102676629B1 (en) 2015-04-29 2024-06-18 래디어스 파마슈티컬스, 인코포레이티드 How to Treat Cancer
RS63311B1 (en) 2016-06-22 2022-07-29 Ellipses Pharma Ltd AR+ METHODS OF BREAST CANCER TREATMENT
KR102881465B1 (en) 2017-01-05 2025-11-04 래디어스 파마슈티컬스, 인코포레이티드 Polymorphic forms of rad1901-2hcl
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
CN112423844B (en) 2018-07-04 2024-08-13 雷迪厄斯制药公司 Polymorphic forms of RAD1901-2HCL
JOP20210218A1 (en) 2019-02-12 2023-01-30 Radius Pharmaceuticals Inc operations and vehicles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
US6316410B1 (en) * 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US6537965B1 (en) * 1998-11-25 2003-03-25 The General Hospital Corporation Amino-terminal modified parathyroid hormone (PTH) analogs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544949B1 (en) * 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
US6537965B1 (en) * 1998-11-25 2003-03-25 The General Hospital Corporation Amino-terminal modified parathyroid hormone (PTH) analogs
US6316410B1 (en) * 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288253B2 (en) 2003-08-08 2007-10-30 Amgen Fremont, Inc. Antibodies directed to parathyroid hormone (PTH) and uses thereof

Also Published As

Publication number Publication date
US7799757B2 (en) 2010-09-21
AU2003251527A1 (en) 2003-12-31
WO2003105772A2 (en) 2003-12-24
EP1551438A2 (en) 2005-07-13
AU2003251527A8 (en) 2003-12-31
US20060058230A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
LT2001004A (en) Fertilizer from sapropel and manufacture thereof
BG104315A (en) Prostaglandine agonists and their application for the treatment of osteal diseases
WO2003105800A3 (en) GALENIC FORM, IN THE FORM OF A FILM ADHERING TO THE MUCOSA, FOR THE ADMINISTRATION OF ACTIVE INGREDIENTS OF CANNABIS
EP0911321A3 (en) Compounds for the treatment of osteoporosis
BR9812837A (en) Process for making a compound, and, compound
BRPI0307702B8 (en) antibody-containing solution formulations
DZ3482A1 (en) SECRETAGOGUES OF THE GROWTH HORMONE
NO20034230D0 (en) 1,2,3,4-tetrahydroisoquinoline derivatives as urotensin II receptor antagonists
BR9407047A (en) Process for separating a protein from an aqueous protein solution
WO1998058911A3 (en) Prostaglandin agonists
BR0213355A (en) pharmaceutical compositions
CA2294078A1 (en) C-peptide specific assay procedure
MXPA04004939A (en) 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them.
MY121054A (en) Calcilytic compounds as calcium receptor antagonists.
PL374080A1 (en) Processes for the preparation of fibrinogen
PT1079803E (en) PROTEIN FORMULATIONS
ATE202483T1 (en) IMMUNTOLERANT PROTHROMBIN COMPLEX PREPARATION
DE60233803D1 (en) 5-CNAC FOR ORAL ADMINISTRATION OF PARATHORMONE FRAGMENTS
WO2003064452A3 (en) Method for the preparation of highly branched polypeptides
NO20014241D0 (en) C16-unsaturated FP-selective prostaglandin analogs
TR200503401T1 (en) Quetiapine new polymorphs of Fumarate
DK0996435T3 (en) Amino acid derivatives useful for the treatment of stroke
MY147518A (en) 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
WO2002083713A3 (en) Echinocandin process
WO1998046632A3 (en) Inhibitors for urokinase receptor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003760386

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006058230

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10516224

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003760386

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10516224

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003760386

Country of ref document: EP